Endo Kazuhira, Masatani Tomomi, Tsuji Akira, Kondo Satoru, Wakisaka Naohiro, Murono Shigeyuki, Yoshizaki Tomokazu
Division of Otolaryngology, Graduate School of Medicine, Kanazawa University, Kanazawa 920-8640, Japan.
Division of Otolaryngology, Graduate School of Medicine, Kanazawa University, Kanazawa 920-8640, Japan.
Auris Nasus Larynx. 2015 Jun;42(3):231-4. doi: 10.1016/j.anl.2014.12.002. Epub 2014 Dec 24.
Hypothyroidism is a late side effect after curative radiotherapy in the head and neck region. Superselective intra-arterial chemotherapy (SSIAC), when combined with radiation (SSIAC-R), shows higher control potential for locally advanced head and neck cancers, which is attributable to a delivery of higher concentrations of chemotherapeutic agents. However, it could enhance damages in the normal tissues. Hypothyroidism is a late adverse effect after curative radiotherapy in the head and neck region. This study focuses on the toxic effect of treatment modality for thyroid function.
A retrospective analysis was performed to examine patients' thyroid function after SSIAC-R for laryngeal and hypopharyngeal cancer.
Hypothyroidism was observed in 21 (77.8%) of 27 patients receiving SSIAC-R, 4 (33.3%) of 12 patients treated with radiation alone, and 7 (41.1%) of 17 who underwent systemic chemoradiotherapy. The number of administered vessels significantly correlated with the incidence of developing hypothyroidism among SSIAC-R treated patients (P=0.03).
Concurrent setting of SSIAC with radiation significantly raises the possibility of hypothyroidism. Therefore, monitoring late complications of therapeutic procedures is essential during follow-up visits.
甲状腺功能减退是头颈部根治性放疗后的晚期副作用。超选择性动脉内化疗(SSIAC)与放疗联合(SSIAC-R)时,对局部晚期头颈部癌症显示出更高的控制潜力,这归因于更高浓度化疗药物的递送。然而,它可能会增加正常组织的损伤。甲状腺功能减退是头颈部根治性放疗后的晚期不良反应。本研究聚焦于治疗方式对甲状腺功能的毒性作用。
进行回顾性分析,以检查接受SSIAC-R治疗喉癌和下咽癌患者的甲状腺功能。
27例接受SSIAC-R治疗的患者中有21例(77.8%)出现甲状腺功能减退,12例单纯接受放疗的患者中有4例(33.3%)出现,17例接受全身放化疗的患者中有7例(41.1%)出现。在接受SSIAC-R治疗的患者中,给药血管数量与发生甲状腺功能减退的发生率显著相关(P=0.03)。
SSIAC与放疗同时进行显著增加了甲状腺功能减退的可能性。因此,在随访期间监测治疗程序的晚期并发症至关重要。